Fig. 2From: The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatmentsVaccination strategy: comparison of relative prevalence reduction using fixed treatment numbers of 20/1,000 PWID per year and vaccinating all who were treated and had a SVR (A); vaccinating an equivalent number independently of treatment history in the community (B); and vaccinating everyone not infected (C). Settings with 75, 50 and 25Â % initial chronic HCV prevalence among PWID, vaccines with 30, 60 and 90Â % efficacies. HCV hepatitis C virus, PWID people who inject drugsBack to article page